Tranexamic acid for melasma: what the evidence shows

Tranexamic acid (TXA) is an antifibrinolytic medication, originally used to reduce bleeding, that has been repurposed as a treatment for melasma. Across multiple meta-analyses of randomized controlled trials, it significantly reduces melasma severity, and the oral route shows the largest effect among the forms studied [1][2]. In practice it is used as a systemic adjunct for moderate, severe, or recurrent melasma, alongside the established foundation of topical lightening therapy and strict sun protection rather than in place of them [3].

This article summarizes what the trial evidence shows about tranexamic acid for melasma, how the different routes compare, and the safety considerations that determine who is a candidate. It is not medical advice; tranexamic acid for melasma is prescribed and monitored by a physician, and is off-label in many settings.

How it is thought to work

Melasma involves overactive pigment production that is strongly influenced by ultraviolet light, hormones, and the interaction between pigment cells and surrounding skin and blood vessels. Tranexamic acid is thought to reduce this pigment-producing signaling and the associated vascular component, which is a different mechanism from topical bleaching agents such as hydroquinone [3]. That difference is why it is often combined with, rather than substituted for, topical therapy.

What the trials show

The evidence base is now substantial. A 2024 meta-analysis and systematic review of 22 randomized trials with 1,280 patients found that tranexamic acid significantly reduced melasma severity scores, with oral administration producing the most substantial decrease, followed by injection and then topical application [1]. A separate updated meta-analysis of 24 randomized trials reached a consistent conclusion: tranexamic acid reduced severity scores across delivery routes, the benefit of adding it to routine treatment was significant, and no serious adverse events occurred, supporting oral tranexamic acid as an effective and reasonably safe option [2]. The broader evidence-based review of melasma similarly describes oral tranexamic acid as a promising systemic adjunct for moderate and recurrent disease [3].

A recurring caution in these analyses is heterogeneity: studies used different doses, durations, and combinations, which limits precise dosing conclusions and points to the need for more standardized protocols [1][2].

Where it fits in treatment

Tranexamic acid does not replace the first-line foundation. The standard of care for melasma remains topical lightening, led by triple-combination cream and hydroquinone, combined with daily broad-spectrum sun protection [3][4]. Tranexamic acid is added when topical therapy alone is insufficient, particularly for moderate to severe or relapsing melasma. Our guides to triple-combination cream and distinguishing types of facial pigmentation cover the rest of the plan.

Safety and candidacy

Because tranexamic acid reduces the breakdown of blood clots, candidacy depends on an individual's clotting risk. It is generally avoided in people with a personal or strong family history of venous thromboembolism, known clotting disorders, certain cardiovascular conditions, or other thrombotic risk factors, and it requires assessment before prescribing [2]. Reported side effects in melasma trials were mostly mild, including gastrointestinal discomfort, skin irritation with topical use, and menstrual changes, with serious events uncommon at the low doses used [1][2].

Adverse events, limitations, and realistic expectations

• Adjunct, not a standalone cure. Tranexamic acid works best with topical therapy and sun protection; melasma is chronic and tends to relapse after any treatment stops [3].
• Oral route is the most supported, but exact dosing and duration are not standardized across studies [1][2].
• Clotting risk gates use. A thorough history is needed, and the medication is avoided in people at elevated thrombotic risk [2].
• Common side effects are usually mild: gastrointestinal upset, menstrual changes, and local irritation with topical forms [1].
• Topical and injected forms are less effective than oral in pooled analyses, though they avoid systemic exposure [1].
• Evidence heterogeneity means results vary between studies and protocols are still being refined [1][2].

Bottom line

Tranexamic acid is an evidence-supported adjunct for melasma, with meta-analyses showing meaningful reductions in severity and the oral route giving the largest effect [1][2]. It complements, rather than replaces, topical lightening and sun protection, and candidacy hinges on clotting risk, so it is prescribed and monitored by a physician [2][3]. Because melasma relapses, tranexamic acid is best viewed as one part of a long-term, sun-protective management plan.

This article is for informational purposes and does not constitute medical advice.